Psoriasis and Related Conditions: Recent Advances and Controversies

Dear Colleagues,

Psoriasis is a chronic, immune-mediated skin disorder that affects approximately 2–3% of the global population. Characterized by the hyperproliferation of keratinocytes and systemic inflammation, it presents with erythematous, scaly plaques and is often associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. Despite significant advances in understanding its pathophysiology, psoriasis remains a complex condition with unresolved questions regarding its triggers, treatment responses, and long-term management.

Recent breakthroughs in immunology have led to the development of targeted biologic therapies, including IL-17 and IL-23 inhibitors, which have revolutionized treatment outcomes. However, the long-term safety, cost, and accessibility of these therapies remain contentious. Additionally, emerging research on the gut–skin axis and the role of microbiota in psoriasis pathogenesis has sparked debate over potential non-traditional treatment avenues, such as probiotics and dietary modifications.

Beyond pharmacologic interventions, controversies persist regarding the impact of environmental factors, stress, and lifestyle on disease progression. Furthermore, disparities in healthcare access raise ethical concerns about treatment equity. This Special Issue aims to explore recent advances in psoriasis research while addressing ongoing controversies that influence clinical decision-making, patient care, and future therapeutic developments.

Prof. Dr. Alin Laurentiu Tatu
Guest Editor

Dr. Elena Niculeţ
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.